Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2017 | Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial | Bahlis N.J.; Corso A.; Mugge L.-O.; Shen Z.-X.; Desjardins P.; Stoppa A.-M.; Decaux O.; De Revel T.; Granell M.; Marit G.; Nahi H.; Demuynck H.; SHANG-YI HUANG ; Basu S.; Guthrie T.H.; Ervin-Haynes A.; Marek J.; Chen G.; Facon T. | Leukemia | 18 | 16 | |
2017 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial | Lu J.; Lee J.H.; SHANG-YI HUANG ; Qiu L.; Lee J.-J.; Liu T.; Yoon S.-S.; Kim K.; Shen Z.X.; Eom H.S.; Chen W.M.; Min C.K.; Kim H.J.; Lee J.O.; Kwak J.Y.; Yiu W.; Chen G.; Ervin-Haynes A.; Hulin C.; Facon T. | British Journal of Haematology | 10 | 11 |